Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Toripalimab with TNT for locally advanced rectal cancer
NCT04518280Phase 2Completed
- Sponsor
- Fudan University
- Start
- May 2021
- Primary completion
- Sep 2023
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in rectal cancer, sponsored by Fudan University. Started May 2021; status: completed.
02
Drugs
toripalimab
03
Conditions
rectal cancer
Beyond the preview
Go deeper on NCT04518280.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04518280.